|
DE19624659A1
(de)
*
|
1996-06-20 |
1998-01-08 |
Klinge Co Chem Pharm Fab |
Neue Pyridylalken- und Pyridylalkinsäureamide
|
|
DE19756236A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19756261A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
|
|
DE19756235A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
|
|
DE19756212A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19818044A1
(de)
*
|
1998-04-22 |
1999-10-28 |
Klinge Co Chem Pharm Fab |
Verwendung von Vitamin-PP-Verbindungen
|
|
TR200101155T2
(tr)
*
|
1998-11-17 |
2001-09-21 |
F. Hoffmann-La Roche Ag |
4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III
|
|
EP1031564A1
(en)
*
|
1999-02-26 |
2000-08-30 |
Klinge Pharma GmbH |
Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
|
|
US6432432B1
(en)
|
1999-03-05 |
2002-08-13 |
Arch Chemicals, Inc. |
Chemical method of making a suspension, emulsion or dispersion of pyrithione particles
|
|
CO5180550A1
(es)
|
1999-04-19 |
2002-07-30 |
Smithkline Beecham Corp |
Inhibidores de fab i
|
|
AR024158A1
(es)
|
1999-06-01 |
2002-09-04 |
Smithkline Beecham Corp |
Compuestos antibacterianos
|
|
ES2231275T3
(es)
|
1999-10-08 |
2005-05-16 |
Affinium Pharmaceuticals, Inc. |
Inhibidores de fab i.
|
|
US6762201B1
(en)
|
1999-10-08 |
2004-07-13 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
|
US6730684B1
(en)
|
1999-10-08 |
2004-05-04 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
|
JP4387804B2
(ja)
|
2001-04-06 |
2009-12-24 |
アフィニアム・ファーマシューティカルズ・インコーポレイテッド |
ＦａｂＩ阻害剤
|
|
FR2823975B1
(fr)
*
|
2001-04-27 |
2003-05-30 |
Sanofi Synthelabo |
Nouvelle utilisation de pyridoindolone
|
|
EP1348434A1
(en)
*
|
2002-03-27 |
2003-10-01 |
Fujisawa Deutschland GmbH |
Use of pyridyl amides as inhibitors of angiogenesis
|
|
RS20050532A
(sr)
|
2003-01-14 |
2007-12-31 |
Arena Pharmaceuticals Inc., |
Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
|
|
EP1768662A2
(en)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Small molecule immunopotentiators and assays for their detection
|
|
DOP2006000010A
(es)
|
2005-01-10 |
2006-07-31 |
Arena Pharm Inc |
Procedimiento para preparar eteres aromáticos
|
|
US20110045065A1
(en)
*
|
2005-07-11 |
2011-02-24 |
Ashok Vasantray Vyas |
Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
|
|
US8067457B2
(en)
|
2005-11-01 |
2011-11-29 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of CCR2
|
|
US8067415B2
(en)
|
2005-11-01 |
2011-11-29 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of CCR2
|
|
EP2054422B1
(en)
|
2006-07-20 |
2017-06-14 |
Debiopharm International SA |
Acrylamide derivatives as fab i inhibitors
|
|
WO2008026018A1
(en)
|
2006-09-01 |
2008-03-06 |
Topotarget Switzerland Sa |
New method for the treatment of inflammatory diseases
|
|
WO2008098374A1
(en)
|
2007-02-16 |
2008-08-21 |
Affinium Pharmaceuticals, Inc. |
Salts, prodrugs and polymorphs of fab i inhibitors
|
|
EP2098231A1
(en)
|
2008-03-05 |
2009-09-09 |
Topotarget Switzerland SA |
Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
|
|
MX2010014310A
(es)
|
2008-06-24 |
2011-02-15 |
Topotarget As |
Derivados de acido escuarico como inhibidores de la nicotinamida.
|
|
CN102186822A
(zh)
|
2008-08-29 |
2011-09-14 |
顶标公司 |
新脲和硫脲衍生物
|
|
CN102421754B
(zh)
*
|
2009-05-12 |
2013-11-27 |
北京世桥生物制药有限公司 |
丙烯酰胺类衍生物及其制备药物的用途
|
|
EP2453883A1
(en)
|
2009-07-17 |
2012-05-23 |
Topo Target A/S |
Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
|
|
WO2011121055A1
(en)
|
2010-03-31 |
2011-10-06 |
Topotarget A/S |
Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
|
|
AR082886A1
(es)
|
2010-09-03 |
2013-01-16 |
Forma Therapeutics Inc |
Compuestos y composiciones farmaceuticas que los contienen
|
|
AR082885A1
(es)
|
2010-09-03 |
2013-01-16 |
Genentech Inc |
Compuestos y composiciones para la inhibicion de nampt
|
|
CN106986856A
(zh)
|
2010-09-03 |
2017-07-28 |
福马Tm有限责任公司 |
作为用于治疗疾病诸如癌症的nampt抑制剂的4‑{[(吡啶‑3‑基‑甲基)氨基羰基]氨基}苯‑砜衍生物
|
|
CN103221410B
(zh)
|
2010-09-22 |
2017-09-15 |
艾尼纳制药公司 |
Gpr119受体调节剂和对与其相关的障碍的治疗
|
|
RU2596185C2
(ru)
*
|
2010-09-29 |
2016-08-27 |
Интервет Интернэшнл Б.В. |
N-гетероарильные соединения
|
|
US20120122924A1
(en)
|
2010-11-15 |
2012-05-17 |
Abbott Laboratories |
Nampt inhibitors
|
|
SG10202010119TA
(en)
|
2010-11-15 |
2020-11-27 |
Abbvie Inc |
NAMPT And Rock Inhibitors
|
|
JP5978293B2
(ja)
|
2011-05-04 |
2016-08-24 |
フォーマ ティーエム， エルエルシー． |
Ｎａｍｐｔを阻害するための新規な化合物および組成物
|
|
JP5872027B2
(ja)
|
2011-05-09 |
2016-03-01 |
フォーマ ティーエム， エルエルシー． |
ニコチンアミドホスホリボシルトランスフェラーゼ（ｎａｍｐｔ）を阻害するためのピペリジン誘導体および組成物
|
|
AR087342A1
(es)
|
2011-07-29 |
2014-03-19 |
Karyopharm Therapeutics Inc |
Moduladores del transporte nuclear que contienen hidrazida y sus usos
|
|
SMT202000347T1
(it)
|
2012-05-09 |
2020-07-08 |
Biogen Ma Inc |
Modulatori di trasporto nucleare e loro usi
|
|
AR091022A1
(es)
|
2012-05-11 |
2014-12-30 |
Abbvie Inc |
Inhibidores del nampt
|
|
US20130303509A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Nampt inhibitors
|
|
EP2852585A1
(en)
|
2012-05-11 |
2015-04-01 |
AbbVie Inc. |
Nampt inhibitors
|
|
MX2014013758A
(es)
|
2012-05-11 |
2015-02-05 |
Abbvie Inc |
Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
|
|
EP2861608B8
(en)
|
2012-06-19 |
2019-06-19 |
Debiopharm International SA |
Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
|
|
EP2925750A1
(en)
*
|
2012-11-29 |
2015-10-07 |
Karyopharm Therapeutics, Inc. |
Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
|
|
US10202366B2
(en)
|
2013-03-15 |
2019-02-12 |
Karyopharm Therapeutics Inc. |
Methods of promoting wound healing using CRM1 inhibitors
|
|
KR102322794B1
(ko)
|
2013-06-21 |
2021-11-05 |
카리오팜 쎄라퓨틱스, 인코포레이티드 |
핵수송 조절인자 및 이의 용도
|
|
JP6397010B2
(ja)
|
2013-07-03 |
2018-09-26 |
カリオファーム セラピューティクス，インコーポレイテッド |
置換されたベンゾフラニル及びベンゾオキサゾリル化合物並びにその使用
|
|
WO2015042414A1
(en)
|
2013-09-20 |
2015-03-26 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and methods of using same
|
|
WO2015054060A1
(en)
*
|
2013-10-09 |
2015-04-16 |
Eli Lilly And Company |
Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
|
|
EP3172205A1
(en)
|
2014-07-23 |
2017-05-31 |
Aurigene Discovery Technologies Limited |
4,5-dihydroisoxazole derivatives as nampt inhibitors
|
|
SG11201700789SA
(en)
|
2014-08-15 |
2017-02-27 |
Karyopharm Therapeutics Inc |
Polymorphs of selinexor
|
|
CA3002540C
(en)
|
2015-01-06 |
2023-11-07 |
Arena Pharmaceuticals, Inc. |
Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
|
|
CN104447486B
(zh)
*
|
2015-01-13 |
2016-06-01 |
佛山市赛维斯医药科技有限公司 |
二烯氟代金刚烷类化合物、其制备方法和用途
|
|
CN104447484B
(zh)
*
|
2015-01-13 |
2016-06-08 |
佛山市赛维斯医药科技有限公司 |
含烷氧苯基和二烯金刚烷结构的化合物、其制备方法和用途
|
|
CN104447483B
(zh)
*
|
2015-01-13 |
2016-07-27 |
佛山市赛维斯医药科技有限公司 |
含苯胺和二烯金刚烷结构的化合物、其制备方法和用途
|
|
JP6838744B2
(ja)
|
2015-06-22 |
2021-03-03 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
|
|
WO2017031323A1
(en)
|
2015-08-18 |
2017-02-23 |
Karyopharm Therapeutics Inc. |
(s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
|
|
TWI730985B
(zh)
*
|
2015-09-15 |
2021-06-21 |
美商艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
|
US10526295B2
(en)
|
2015-12-31 |
2020-01-07 |
Karyopharm Therapeutics Inc. |
Nuclear transport modulators and uses thereof
|
|
US10858347B2
(en)
|
2015-12-31 |
2020-12-08 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and uses thereof
|
|
US10709706B2
(en)
|
2015-12-31 |
2020-07-14 |
Karopharm Therapeutics Inc. |
Nuclear transport modulators and uses thereof
|
|
DK3419628T3
(da)
|
2016-02-26 |
2021-01-11 |
Debiopharm Int Sa |
Medikament til behandling af diabetiske fodinfektioner
|
|
EP3279192A1
(en)
|
2016-08-05 |
2018-02-07 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Piperidine derivatives for use in the treatment of pancreatic cancer
|
|
WO2018086703A1
(en)
|
2016-11-11 |
2018-05-17 |
Bayer Pharma Aktiengesellschaft |
Dihydropyridazinones substituted with phenylureas
|
|
WO2018098472A1
(en)
|
2016-11-28 |
2018-05-31 |
Karyopharm Therapeutics Inc. |
Crm1 inhibitors for treating epilepsy
|
|
CN107827897A
(zh)
*
|
2017-10-23 |
2018-03-23 |
青岛大学 |
一种手性七元螺环吲哚酮类化合物的合成方法
|
|
EP3746079A1
(en)
|
2018-01-31 |
2020-12-09 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
EP3787612A4
(en)
|
2018-05-04 |
2021-11-17 |
Remedy Plan, Inc. |
CANCER TREATMENTS AGAINST CANCER STEM CELLS
|
|
CN108558840B
(zh)
*
|
2018-06-04 |
2020-11-06 |
上海交通大学 |
水溶性氮杂α-萘黄酮类化合物及其制备方法和医药用途
|
|
JP7397011B2
(ja)
|
2018-06-06 |
2023-12-12 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
Ｓ１ｐ１受容体に関連する状態を治療する方法
|
|
ES2944535T3
(es)
|
2019-02-14 |
2023-06-22 |
Debiopharm Int Sa |
Formulación de afabicina, método para preparar la misma
|
|
UA129222C2
(uk)
|
2019-06-14 |
2025-02-12 |
Дебіофарм Інтернешнл С.А. |
Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою
|
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
PH12022551081A1
(en)
|
2019-11-06 |
2024-06-19 |
Remedy Plan Inc |
Cancer treatments targeting cancer stem cells
|
|
CA3217380A1
(en)
|
2021-05-13 |
2022-11-17 |
Yushma Bhurruth-Alcor |
Nampt inhibitors and uses thereof
|